Stephens & Co. Initiates Coverage On Blueprint Medicines with Overweight Rating, Announces Price Target of $140
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Sudan Loganathan initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with an Overweight rating and a price target of $140.
May 14, 2024 | 9:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines receives an Overweight rating from Stephens & Co. with a price target of $140, indicating a positive outlook on the stock.
The initiation of coverage by Stephens & Co. with an Overweight rating and a high price target suggests a strong bullish outlook for Blueprint Medicines. This endorsement by a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100